US 12,472,237 B2
Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit
Heinz Gulle, Gross Enzersdorf (AT); Rahul Kumar Singh, Milwaukee, WI (US); Julia Rabas, Hurlach (DE); Eva Reinauer, Eurasburg (DE); and Stella Grosso, Martinsried (DE)
Assigned to BAXTER INTERNATIONAL INC., Deerfield, IL (US); BAXTER HEALTHCARE SA, Glattpark (CH); and LEUKOCARE AG, Martinsried/Munich (DE)
Filed by BAXTER INTERNATIONAL INC., Deerfield, IL (US); BAXTER HEALTHCARE SA, Glattpark (CH); and LEUKOCARE AG, Martinsried/Munich (DE)
Filed on Dec. 9, 2022, as Appl. No. 18/078,213.
Claims priority of provisional application 63/266,239, filed on Dec. 30, 2021.
Prior Publication US 2023/0210958 A1, Jul. 6, 2023
Int. Cl. A61L 24/10 (2006.01); A61K 31/155 (2006.01); A61K 31/4172 (2006.01); A61K 31/724 (2006.01); A61K 38/36 (2006.01); A61K 38/48 (2006.01); A61P 17/02 (2006.01)
CPC A61K 38/363 (2013.01) [A61K 31/155 (2013.01); A61K 31/4172 (2013.01); A61K 31/724 (2013.01); A61K 38/4833 (2013.01); A61P 17/02 (2018.01)] 15 Claims
 
1. A fibrinogen solution consisting essentially of:
67-106 mg/ml human fibrinogen,
0.6-5 mg/ml human Factor XIII,
2250-3750 KIU/ml synthetic aprotinin,
0.63 g/l arginine,
20.00 g/l histidine,
1.80 g/l guanidine—HCl, and
3.15 g/l NaCl,
wherein the fibrinogen solution comprises a total protein concentration of 96-125 mg/ml and an osmolality of 481 mOsmol/kg.